Blueprint Medicines Corporation
BPMC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $5,482 | $5,586 | $2,613 | $6,268 |
| - Cash | $102 | $71 | $120 | $210 |
| + Debt | $469 | $774 | $242 | $111 |
| Enterprise Value | $5,849 | $6,289 | $2,736 | $6,169 |
| Revenue | $509 | $249 | $204 | $180 |
| % Growth | 104% | 22.2% | 13.3% | – |
| Gross Profit | $489 | $237 | $186 | $162 |
| % Margin | 96% | 94.9% | 91.3% | 90% |
| EBITDA | $19 | -$470 | -$515 | -$628 |
| % Margin | 3.8% | -188.6% | -252.6% | -348.9% |
| Net Income | -$67 | -$507 | -$558 | -$644 |
| % Margin | -13.2% | -203.3% | -273.2% | -357.7% |
| EPS Diluted | -1.07 | -8.37 | -9.35 | -11.01 |
| % Growth | 87.2% | 10.5% | 15.1% | – |
| Operating Cash Flow | -$193 | -$437 | -$502 | -$299 |
| Capital Expenditures | -$5 | -$16 | -$9 | -$261 |
| Free Cash Flow | -$197 | -$453 | -$511 | -$560 |